Media

Teewinot Releases:

November 26, 2019  Teewinot Life Sciences to Participate at the 31st Annual Piper Jaffray Healthcare Conference in New York

November 6, 2019  Teewinot Life Sciences to Participate at the 2nd Annual Cowen Cannabis Conference in Boston

October 17, 2019  Teewinot Life Sciences Announces Availability of Cannabinol for Commercial Cannabinoid Market

September 4, 2019  Teewinot Life Sciences Expands First In Class Intellectual Property Portfolio

May 22, 2019  Teewinot Life Sciences Announces Executive Leadership Changes

September 4, 2018 Teewinot Life Sciences Corporation Announced Today Grant Of A Canadian Patent With Broad Claims To Biosynthetic Production Of Cannabinoids

August 28, 2018 Teewinot Life Sciences Corporation Announced Today Grant of a U.S. Patent with Claims to Cannabinoid Formulations

February 5, 2018 Teewinot Life Sciences Corporation’s Subsidiary, Teewinot Technologies, Ltd., Announced Today: Grant of a New Patent with Broad Claims to Biosynthetic Production of Cannabinoids

January 22, 2018 Teewinot Life Sciences Corporation’s Subsidiary, Teewinot Technologies, Ltd. Announced Today: Grant of a New Patent with Broad Claims to Biosynthetic Production of Cannabinoid Pharmaceuticals

November 27, 2017 Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, to Present at CBI’s Biopharma Forum on Cannabis-Based Therapies

May 22, 2017 Teewinot Life Sciences Corporation Announces New Cannabis Genome Research Program

May 1, 2017 Teewinot Life Sciences Corporation, a Global Leader in Pharmaceutical Cannabinoid Production, Secures $12.3 Million Series B Round

March 20, 2017 Teewinot Life Sciences and Noramco sign letter of intent to produce cannabinoids with CannSynthesis™ biocatalysis technology

March 7, 2017 Teewinot Life Sciences Corporation’s Subsidiary, Full Spectrum Laboratories, Ltd., Announced Today: Grant of an Important U.S. Patent with Broad Claims to Biosynthetic Production of Cannabinoids

January 3, 2017 Teewinot Life Sciences’ Irish Subsidiary Full Spectrum Laboratories, Ltd. Secures a New U.S. Patent for Biosynthesis of Cannabinoids

Teewinot in the News:

November 4, 2019 Teewinot Highlighted by Bloomberg Law for Intellectual Property Portfolio

September 10, 2019  Pharma’s Almanac Highlights Teewinot’s CannSynthesis® Platform And The Benefits Of Biosynthetic Cannabinoids

July 25, 2019  Teewinot CEO Michael Luther Interviewed on Daniel Levine’s “The Bio Report”

July 6, 2019  Teewinot CEO Michael Luther Highlighted in Marijuana Business Magazine “Industry Players”

February 8, 2018 Teewinot collects patents to make cannabinoids in US and Ireland

February 6, 2018 NetworkNewsAudio – Teewinot Life Sciences Corporation Interview

November 15, 2017 ALGAE DYNAMICS CORP SECURES US $250,000 INVESTMENT FROM TEEWINOT LIFE SCIENCES CORPORATION

July 11, 2017 Teewinot Life Sciences Corporation in the Tampa Bay Business Journal, “These Tampa Bay companies drew the most venture capital backing in 2Q 2017”

July 11, 2017 Teewinot Life Sciences Corporation in the Tampa Bay Times, “One day, the Tampa Bay area will land its Chewy”

June 17, 2017 Teewinot Life Sciences Corporation’s Jeff Korentur in The Medicine Maker, “A View From the Biosynthetic Bridge”

June 2, 2017 Teewinot Life Sciences Corporation in PharmaTech, “Accessing Cannabinoids Using Biocatalysis”

March 7, 2017 Teewinot Life Sciences Corporation in in-PharmaTechnologist.com, “Nemus hires Catalent to formulate second chemo-induced nausea drug”

February 22, 2017 Teewinot Life Sciences in CBInsights, “Grapeless Wine And Cowless Milk: 60+ Synthetic Biology Startups In A Market Map”

February 16, 2017 Teewinot Life Sciences in Outsourcing-Pharma, “Teewinot ups cannabinoid production capabilities”

February 14, 2017 Teewinot Life Sciences in PRN, “Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series”

February 8, 2017 CEO, Jeffrey Korentur, quoted in in-Pharma, “Pot luck? Medical marijuana’s ‘questionable quality’ no threat to pharma R&D”

January 5, 2017 Patented biosynthesis produces ‘authentic, standardized cannabinoids’ for pharma

Media Relations Contact

Contact: Kellen Murphy
Email: kellen@tlscorp.com
Number: (813) 607-2909